Curium’s Pylclari Receives EC’s Marketing Authorization for Adults with Prostate Cancer
Shots:
- The EC has granted marketing authorization to Pylclari, an innovative 18F-PSMA PET tracer for the detection of PSMA+ lesions with PET in adults with prostate cancer
- The PSMA-PET tracer is indicated for the following clinical settings: Primary staging of patients with high-risk prostate cancer prior to initial curative therapy & to localize recurrence of prostate cancer in patients with a suspected recurrence based on increasing serum PSA levels after primary treatment with curative intent
- In May 2021, the US FDA approved piflufolastat F 18 (Pylarify) inj. to identify suspected metastasis or recurrence in patients with prostate cancer, based on data from the P-III trials (OSPREY) & (CONDOR)
Ref: Globenewswire | Image: Curium
Related News:- Curium's Pulmotech MAA Receives the US FDA's Approval for Lung Imaging
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
